Euroland - Daiichi Sankyo Co., Ltd. - Latest press releases / Share Data / Share Price / Chart / Graph / Technical Analysis / Financial Information / Year In Brief / Strategy / Goals / Balance Sheet / Income Statement / Cash Flow / Annual Reports / Interim Reports / Press Releases / Dividends

TimeZone

Currency

Language

HOME

ABOUT US MY EUROLAND USERS’ PAGE CORPORATE SITES CONTACT US SITE OVERVIEW LINKS


Back

Corporate Information
	Company Presentation
	Mission
News & Reports
	Reports
	Press releases

Share Tools
	Share Graph

http://www.daiichisankyo.com

Daiichi Sankyo Co., Ltd.
3-5-1, Nihonbashi-honcho, Chuo-ku,
103-8426 Tokyo
JAPAN
Tel: ‎+81-3-6225-1111

Print this page

Send to a Friend E-mail this page to your friend

Disclaimer

Latest press releases

Go to press releases on company’s homepage

(2024-06-28)	Arbitration Dispute Between Daiichi Sankyo and Seagen Ends(203KB)
(2024-06-27)	Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer(200.3KB)
(2024-06-24)	EZHARMIA® Approved in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Peripheral T-Cell Lymphoma(223.7KB)PDF
(2024-06-02)	ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy (463.7KB)
(2024-05-27)	Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial(173.2KB)
(2024-05-22)	Daiichi Sankyo Establishes Two Research Institutes in the U.S. and EU(81.1KB)
(2024-05-21)	Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO (230.6KB)
(2024-05-14)	Daiichi Sankyo Announces Appointments of Directors(251.4KB)
(2024-04-29)	ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial(395.1KB)PDF
(2024-04-25)	Daiichi Sankyo Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB)
(2024-04-06)	ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB)
(2024-04-03)	REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB)
(2024-04-02)	Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB)
(2024-03-29)	Daiichi Sankyo Announces Global Management Structure and CxOs(179.6KB)
(2024-03-14)	Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer(190.8KB)PDF
(2024-03-04)	Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer (200.1KB)
(2024-03-04)	Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets(405KB)
(2024-02-21)	Daiichi Sankyo Announces Global Management Structure and Corporate Officers(266.3KB)
(2024-02-19)	Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer (219.1KB)
(2024-01-31)	EZHARMIA® Supplemental New Drug Application Submitted in Japan for Patients with Peripheral T-Cell Lymphoma(217.5KB)
(2024-01-29)	ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors(365.7KB)
(2024-01-17)	U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen(147.6KB)
(2024-01-05)	Daiichi Sankyo Pledges Support for Victims of the Noto Peninsula Earthquake(121.7KB)
(2024-01-03)	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation (120.6KB)

2024

Corporate Information

News & Reports

Share Tools